Work

Renal glukosehomeostase og hyperglykemi ved type 2 diabetes mellitus, og terapeutiske muligheter ved SGLT2-hemmere

Year: 2017
Type: dissertation
Abstract: Background: The persistent hyperglycaemia in patients with type 2 diabetes mellitus is strongly associated with microvascular and macrovascular complications.There are many hypoglycaemic agents available, with SGLT2-inihibtors representing a novel mechanism for treating hyperglycaemia in patients with type 2 diabetes mellitus.Objective: The objective of this study is to describe the role of the kidney in glucose homeostasis, changes in the kidney in patients with type 2 diabetes mellitus and to describe the mechanism of action of the SGLT2-inhibitors.Furthermore, the efficacy and safety of the drug will be assessed.Method: This study is a literature review based upon a non-systematic search in Ovid MEDLINE and PubMed.Reference lists of relevant articles were examined.Results: The kidneys play a substantial role in glucose homeostasis, filtrating approximately 180 grams of glucose every day.Physiologically, almost all glucose is reabsorbed.In the diabetic kidney, the capacity of reabsorption of glucose is increased.The SGLT2-inhibitors will inhibit some of the kidneys capacity of glucose reabsorption, with glycosuria and natriuresis, and reduced average plasma glucose concentration and HbA1c as a result.There is consistent evidence in the literature that SGLT2-inhibitors reduce HbA1c, and that it has a favourable effect on blood pressure and weight.A recent study has also shown that empagliflozin reduce the rates of death from cardiovascular causes in type 2 diabetes patients with established cardiovascular disease.By inhibiting the glucose and sodium reabsorption, the drug may also impose a protective effect on the glomerulus.Compared to other hypoglycaemic agents, it has similar ability to reduce average plasma glucose.Conclusion: In type 2 diabetes patients with established cardiovascular disease, studies has shown that the drug has favourable effects beyond glycaemic control, and if the results can be replicated, it may play a substantial role as an antidiabetic.However, these effects cannot necessarily be extrapolated to diabetes patients in general, and further trials are necessary to establish the efficacy and safety of the drug.
Institution: University of Oslo
Language: Norwegian
Field: Medicine
Open Access status: green
OpenAlex ID: W2740285234
Cites: 35
Cited by:
Related to: 10